Skip to main content

Table 2 Variations in serum androgen levels and in insulin sensitivity indexes in the general and sub-populations distinguished on the basis of the presence/absence of adverse obstetric outcomes

From: Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes

Group

PCOS group

Control group

 

Total population

Adverse outcome

No adverse outcome

Total population

Adverse outcome

No adverse outcome

T (ng/mL)

      

   Δ(0-12)

0.11 ± 0.02*

0.15 ± 0.01°

0.05 ± 0.02

0.03 ± 0.001

0.04 ± 0.003

0.03 ± 0.002

   Δ(0-20)

0.22 ± 0.01*

0.29 ± 0.02°

0.16 ± 0.01

0.02 ± 0.002

0.03 ± 0.002

0.02 ± 0.004

   Δ(0-32)

0.31 ± 0.02*

0.36 ± 0.01°

0.24 ± 0.01

0.02 ± 0.001

0.03 ± 0.002

0.02 ± 0.004

A (ng/mL)

      

   Δ(0-12)

0.16 ± 0.01

0.17 ± 0.01

0.17 ± 0.02

0.13 ± 0.01

0.16 ± 0.01

0.12 ± 0.04

   Δ(0-20)

0.44 ± 0.02

0.43 ± 0.02

0.45 ± 0.02

0.22 ± 0.01

0.20 ± 0.04

0.23 ± 0.03

   Δ(0-32)

0.74 ± 0.01

0.74 ± 0.01

0.74 ± 0.02

0.25 ± 0.01

0.25 ± 0.03

0.24 ± 0.01

DHEAS (ng/mL)

      

   Δ(0-12)

32.25 ± 2.51*

35.69 ± 2.1°

28.97 ± 2.8

10.51 ± 2.16

11.01 ± 2.31

9.43 ± 2.77

   Δ(0-20)

175.11 ± 4.92*

184.63 ± 5.2°

166.87 ± 4.5

9.70 ± 1.97

11.26 ± 2.05

9.04 ± 2.52

   Δ(0-32)

185.28 ± 6.42*

193.33 ± 6.13°

172.54 ± 6.98

11.34 ± 2.43

12.12 ± 3.06

9.90 ± 2.28

SHBG (nmol/L)

      

   Δ(0-12)

10.71 ± 3.15*

7.48 ± 3.51°

14.13 ± 4.24

26.76 ± 8.34

25.43 ± 8.96

27.61 ± 7.56

   Δ(0-20)

90.36 ± 9.44*

73.55 ± 8.34°

116.45 ± 9.08

141.37 ± 9.21

139.12 ± 12.02

153.11 ± 8.42

   Δ(0-32)

93.69 ± 8.81*

72.79 ± 7.53°

119.81 ± 8.90

275.18 ± 12.88

268.07 ± 11.32

282.16 ± 13.02

FAI (%)

      

   Δ(0-12)

-1.13 ± 0.73*

-0.69 ± 0.34°

-1.54 ± 0.77

-2.53 ± 0.47

-2.47 ± 0.29

-2.59 ± 0.42

   Δ(0-20)

-0.92 ± 0.51*

-0.12 ± 0.09°

-1.88 ± 0.54

-3.13 ± 0.62

-2.99 ± 0.89

-3.23 ± 0.55

   Δ(0-32)

-1.01 ± 0.90*

-0.35 ± 0.06°

-1.73 ± 0.49

-3.35 ± 0.51

-3.19 ± 1.01

-3.42 ± 0.47

Fasting insulin (μU/mL)

      

   Δ(0-12)

1.93 ± 0.36*

2.10 ± 0.21°

1.24 ± 0.43°

1.02 ± 0.52

1.26 ± 0.73

0.98 ± 0.36

   Δ(0-20)

2.64 ± 1.13*

2.98 ± 1.05°

2.12 ± 1.02°

1.41 ± 0.24

1.58 ± 0.89

1.14 ± 0.41

   Δ(0-32)

2.71 ± 1.55*

3.12 ± 1.23°

2.31 ± 1.51°

1.85 ± 0.73

2.22 ± 0.93

1.44 ± 0.67

GIR (mg/10 -4 U)

      

   Δ(0-12)

0.34 ± 0.01*

0.22 ± 0.01°

0.41 ± 0.01

0.12 ± 0.03

0.09 ± 0.01

0.18 ± 0.02

   Δ(0-20)

1.02 ± 0.03*

0.78 ± 0.04°

1.76 ± 0.02

0.13 ± 0.05

0.10 ± 0.01

0.17 ± 0.05

   Δ(0-32)

1.33 ± 0.06*

1.02 ± 0.02°

1.64 ± 0.01

0.25 ± 0.03

0.20 ± 0.04

0.30 ± 0.01

HOMA

      

   Δ(0-12)

0.62 ± 0.01*

0.84 ± 0.02°

0.46 ± 0.01

-0.18 ± 0.04

-0.20 ± 0.05

-0.10 ± 0.03

   Δ(0-20)

0.91 ± 0.04*

1.02 ± 0.03°

0.86 ± 0.02

-0.27 ± 0.12

-0.37 ± 0.15

-0.18 ± 0.10

   Δ(0-32)

1.12 ± 0.06*

1.48 ± 0.05°

0.89 ± 0.03

-0.26 ± 0.06

-0.34 ± 0.05

-0.19 ± 0.06

  1. *p < 0.05 vs. control group; °p < 0.05 vs. no adverse outcome.